Health care–associated infections in all patients (with or without diabetes)
| Outcome measures . | TXA (n = 307) . | Placebo (n = 306) . | RR (95% CI) . | P . |
|---|---|---|---|---|
| Primary end point | ||||
| Health care–associated infection | 79 (25.7) | 100 (32.7) | 0.79 (0.61-1.01) | .059 |
| Secondary end points* | 35 (11.4) | 36 (11.8) | 0.97 (0.63-1.50) | .89 |
| Pneumonia | ||||
| SSI | 44 (14.3) | 63 (20.6) | 0.70 (0.49-0.99) | .041 |
| Superficial | 37 (12.1) | 55 (18.0) | 0.67 (0.46-0.99) | .040 |
| Deep | 8 (2.6) | 9 (2.9) | 0.89 (0.35-2.27) | .80 |
| Organ space | 2 (0.7) | 3 (1.0) | 0.66 (0.11-3.95) | .69† |
| Sepsis | 37 (12.1) | 48 (15.7) | 0.87 (0.70-1.06) | 0.19 |
| Bacteremia | 2 (0.7) | 3 (1.0) | 0.66 (0.11-3.95) | 0.69† |
| Catheter line infection | 2 (0.7) | 1 (0.3) | 1.99 (0.18-21.9) | 0.99† |
| Outcome measures . | TXA (n = 307) . | Placebo (n = 306) . | RR (95% CI) . | P . |
|---|---|---|---|---|
| Primary end point | ||||
| Health care–associated infection | 79 (25.7) | 100 (32.7) | 0.79 (0.61-1.01) | .059 |
| Secondary end points* | 35 (11.4) | 36 (11.8) | 0.97 (0.63-1.50) | .89 |
| Pneumonia | ||||
| SSI | 44 (14.3) | 63 (20.6) | 0.70 (0.49-0.99) | .041 |
| Superficial | 37 (12.1) | 55 (18.0) | 0.67 (0.46-0.99) | .040 |
| Deep | 8 (2.6) | 9 (2.9) | 0.89 (0.35-2.27) | .80 |
| Organ space | 2 (0.7) | 3 (1.0) | 0.66 (0.11-3.95) | .69† |
| Sepsis | 37 (12.1) | 48 (15.7) | 0.87 (0.70-1.06) | 0.19 |
| Bacteremia | 2 (0.7) | 3 (1.0) | 0.66 (0.11-3.95) | 0.69† |
| Catheter line infection | 2 (0.7) | 1 (0.3) | 1.99 (0.18-21.9) | 0.99† |